FilingReader Intelligence
Henlius reports profit increase, executive changes, expansion plans
March 27, 2025 at 05:38 PM UTC•By FilingReader AI
Shanghai Henlius Biotech (HKEX:2696) reported a year of substantial growth and strategic realignment, according to its annual results announcement for the year ended December 31, 2024, and related filings. The company's total revenue increased by 6.1% to RMB 5,724.4 million, with a total profit of RMB 820.5 million, representing a profit surge of RMB 274.5 million from the previous year.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
(1) RE-DESIGNATION OF DIRECTOR (2) CHANGE OF AUTHORISED REPRESENTATIVE AND (3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATIONMarch 24, 2025 at 10:34 AM UTC
INSIDE INFORMATION ANNOUNCEMENT - PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANYMarch 24, 2025 at 10:45 AM UTC
CONTINUING CONNECTED TRANSACTIONS - (1) GENERAL PROCUREMENT FRAMEWORK AGREEMENT AND (2) IT RELATED PROCUREMENT FRAMEWORK AGREEMENTMarch 24, 2025 at 10:45 AM UTC
HKEX:2696•Hong Kong Exchange
News Alerts
Get instant email alerts when Shanghai Henlius Biotech, Inc publishes news
Free account required • Unsubscribe anytime